ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~3#܈ ~~7#܈ ~~<#܈ ~~4#܈ ~~83ffff̙̙3f3fff3f3f33333f33"]CONCERT PHARMACEUTICALS INC INone,+TABLE OF CONTENTSLMARKET INFORMATION&]54PURCHASE OF EQUITY SECURITIES F64StockBased Compensation&8Comparison of the years ended D&Research and development expens#Comparison of the years (1)$Research and development (1)* Cash flowsContractual obligations$5INDEX TO FINANCIAL STATEMENTSZBasis for Opinion~?Basis for Opini (1))eBasis for Opini (2)Basis for Opini (3) J3 Fair Value Measurements&NOTES TO CONSOLIDATED FINANCIAL&4 Cash Cash Equivalents and Inv#4 Cash Cash Equivalents (1)<6 Property and Equipment&,&7 Accrued Expenses and Other Li!j6NOTES TO CONSOLIDATED (1)!GNOTES TO CONSOLIDATED (2)!WNOTES TO CONSOLIDATED (3)!wmNOTES TO CONSOLIDATED (4)&;}Stockbased compensation expense!dNOTES TO CONSOLIDATED (5)!/NOTES TO CONSOLIDATED (6)!NOTES TO CONSOLIDATED (7)!NOTES TO CONSOLIDATED (8)&=15 Loan Payable and Warrant to &*18 Quarterly Financial Informat"18 Quarterly Financial (1)&EXECUTIVE OFFICERS AND DIRECTOR&+2017 Summary Compensation Table&FNarrative to Summary Compensati&5W111Outstanding Equity Awards at&i|Payments and benefits provided 4Director Compensation Director Compen (1)&Item 12 Security Ownership of C&Item 14 Principal Accountant FePart IV  Part IV (1)N10 Miscellaneous .LEASE SUMMARY SHEETF234LIST OF EXHIBITS(^5TABLE OF CONTENTSx5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES&XLANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)&TENANT WORK INSURANCE REQUIREME!CTENANT WORK INSURANCE (1)!,TENANT WORK INSURANCE (2)&8SUMMARY OF DIRECTOR COMPENSATIO%GSubsidiaries of the Registrant l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<NoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } %} $ }       %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018:2_____________________CONCERT PHARMACEUTICALS, INC.       Delaware   20-4839882' (State or other jurisdiction of  (I.R.S. Employer& incorporation or organization)  Identification No.)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hg[OC7f=PF0*8X> @ l  *  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U} $ } 8} $ } } $ } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018 None               Large accelerated filer  ?  Accelerated filer  x     Non-accelerated filer 7 /? (Do not check if a smaller reporting company) ! Smaller reporting company  ?Emerging Growth Company x$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.}qe?] ]=PF0*8X> @ l  O.<3GYK  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } y } $ } :} $ }  O     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018TABLE OF CONTENTS           PART I      Item 1.  Business ~ Item 1A. Risk Factors~ bItem 1B.!Unresolved Staff Comments~ Item 2. Properties~ Item 3.Legal Proceedings~ Item 4.Mine Safety Disclosures~ PART IIItem 5..&Market for Registrant?s Common Equity,~ .&Related Stockholder Matters and Issuer&Purchases of Equity SecuritiesItem 6.Selected Financial Data~ Dl|pdXE!L(_;x  !"#$%&'()*+,-./0123456789:;<=>?   !Item 7.!,!$Management?s Discussion and Analysis!~ !""8"0of Financial Condition and Results of Operations###$Item 7A.$0$(Quantitative and Qualitative Disclosures$~ $*%%%About Market Risk&&&'Item 8.'.'&Financial Statements and Supplementary'~ '*(( (Data)))*Item 9.*5*-Changes in and Disagreements with Accountants*~ *++.+&on Accounting and Financial Disclosure,,,-Item 9A.--Controls and Procedures-~ -.../Item 9B.//Other Information/~ /001PART III112223Item 10.333+Directors, Executive Officers and Corporate3~ 3444 Governance5556Item 11.66Executive Compensation6~ 67778Item 12.808(Security Ownership of Certain Beneficial8~ 89959-Owners and Management and Related Stockholder:::Matters;;;<Item 13.<0<(Certain Relationships and Related Person<~ <==/='Transactions, and Director Independence>>>?Item 14.?.?&Principal Accountant Fees and Services?~ ?D lsX4} @]>[0 S@ABCDEFGHIJKLMN@@APART IVAABBBCItem 15.C2C*Exhibits and Financial Statement SchedulesC~ CDDEItem 16.EEForm 10-K SummaryE~ EFFFG EXHIBIT INDEXG~ GHHHHHI SIGNATURESI~ IJK$L____________________________1M)Created by Morningstar Document Research.0N(http://documentresearch.morningstar.com/")c'=PF0*8X> @J NNMMLLIIGGAA11  l  w\  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTS!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } I"} $                            %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018MARKET INFORMATION            High  Low$ Year Ended December 31, 2017      First Quarter  Gzn2@   33333!@  Second Quarter  333330@   Q(@  Third Quarter0@(\*@Fourth Quarter =@Q+@$Year Ended December 31, 2016 First Quarterq= ף3@RQ(@Second Quarter(\/@#@ Third Quarter(\(@q= ף"@Fourth Quarter(\%@q= ףp@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8%{ocWPuBgtL=PF0*8X> @       l  3Ly  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 7} $ 3     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018'54PURCHASE OF EQUITY SECURITIES                        Years ended December 31,- %(in thousands, except per share data) ~  ~  ~ ~ ~ z ~ v Results of Operations            Total revenue ~ N  ~   ~   ~   ~  Operating expenses:    Research and development~ >~ A ~  V  ~ J~ zT"General and administrative~ nH~ Z ~    ~ Ҷ~ r} Total operating expenses~  ~ 6" ~  V  ~ d~ %Income (Loss) from operations~ ~  ~  R  ~ !~ 0(Interest and other income (expense), net~  *~  ~    ~ ~ J,$(Benefit) Provision for income taxes~ R ? ~     ? ?Net income (loss)~ ^~  ~  y  ~ ~ b.&Net income (loss) applicable to common~ n~  ~  y  ~ ~ 2stockholders - basic.&Net income (loss) applicable to common~ ~  ~  y  ~ ~ 2stockholders - dilutedEarnings Per Share   .&Net income (loss) per share applicable@= ףp=  = ףp=?  ~ (\&to common stockholders - basic.&Net income (loss) per share applicable= ףp=@= ףp=  q= ףp?  ~ (\( to common stockholders - diluted0(Weighted-average number of common shares~ a~ f[ ~  J  ~ ~ 2DolznbVJN_Xv!YY// !"#$%&'()*+,-./0126 .used in net income (loss) per share applicable&!to common stockholders - basic0"(Weighted-average number of common shares"~ "Jn""~ "f["" ~ " [" " ~ """~ "2"6#.used in net income (loss) per share applicable($ to common stockholders - diluted%Financial Condition%%%%% % % %%%!&Cash and cash equivalents&~ &F&&~ &y&& ~ & z& & ~ &R&&~ &&''Investments, available for sale'~ '2 ''~ ':e'' ~ ' B' ' ~ '''~ 'g'(Working capital(~ () ((~ ((( ~ ( &d( ( ~ (((~ (B() Total assets)~ )b ))~ ) )) ~ ) ) ) ~ )'))~ )vm)*Deferred revenue*~ ***~ * ** ~ * * * ~ *6**~ *2*%+Loan payable, net of discount+ +?++ +?++  + ?+ + ~ +n++~ ++.,&Redeemable convertible preferred stock, ,?,, ,?,,  , ?, ,  ,?,,~ ,,,-$Total stockholders? equity (deficit)-~ -B --~ -j9-- ~ - .- - ~ -X--~ -b(-./$0____________________________11)Created by Morningstar Document Research.02(http://documentresearch.morningstar.com/* hpD2XtZ=PF0*8X> @w221100------ ----,,,,,, ,,,,++++++ ++++****** ****)))))) ))))(((((( (((('''''' ''''&&&&&& &&&&"""""" """"                      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U} $ }  } $} $ }  } $} $ }  } $                       %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018"64Stock-Based Compensation             Year ended December 31,  ~  ~  ~ ~ Expected volatility  S@ %  (\S@ %  QXR@ %  Expected term   6.0 years    6.0 years    6.0 years Risk-free interest rate(\@ %(\? % ףp= ?  %Expected dividend yield ? % ? % ?  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.sg[OB^=PF0*8X> @:       l  !"  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U5}  $ !                                 %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018@8Comparison of the years ended December 31, 2017 and 2016                Year ended December 31,   (in thousands) ~  ~   Change Revenue:      4 ,License and research and development revenue ~   ~   ~ B  Other revenue~ V ? ~  V  Total revenue~ N~  ~   Operating expenses:   Research and development~ >~ A ~  b "General and administrative~ nH~ Z ~  h  Total operating expenses~  ~ 6" ~  v %Income (Loss) from operations~ ~  ~  " Investment income~ ~  ~     Other income~ F8 ? ~  F8 "Interest and other expense~ F ? ~  F &Loss on extinguishment of debt~  ? ~   )!Income (Loss) before income taxes~ ~  ~  . ,$(Benefit) Provision for income taxes~ R ? ~  R Net income (loss)~ ^~  ~   $____________________________1)Created by Morningstar Document Research.DlaUI=1BzFT&fF k 0 (http://documentresearch.morningstar.com/H=PF0*8X> @1                     l  n  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended DComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 0} $                            %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018)!Research and development expenses            Year ended December 31, (in thousands) ~  ~       CTP-543 external costs ~ nb  ~ v CTP-656 external costs~ 0~ CTP-730 external costs~ N~ ~JZP-386 external costs ?~ N)!External costs for other programs~ &~ 0(Employee and contractor-related expenses~ ~ #Facility and other expenses~ >9~ n6/'Total research and development expenses~ >~ A$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8<xl`THS;`gui]5=PF0*8X> @      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensResearch and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U5}  $                                 %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018@8Comparison of the years ended December 31, 2016 and 2015                Year ended December 31,   (in thousands) ~  ~ ~  Change Revenue:      4 ,License and research and development revenue ~   ~ f  ~   Other revenue ?~  ~  V Milestone revenue ?~ B ~  c  Total revenue~ ~  ~   Operating expenses:   Research and development~ A~ V ~  ~ "General and administrative~ Z~  ~  Z  Total operating expenses~ 6"~ V ~   %(Loss) Income from operations~ ~ R ~  6] Investment income~ ~  ~   "Interest and other expense ?~ . ~   )!(Loss) Income before income taxes~ ~ n ~  g "Provision for income taxes ?~  ~  N Net (loss) income~ ~ y ~  m $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/D laUI=1BzF-0gA |pd<=PF0*8X> @r.                    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 0} $                            %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018)!Research and development expenses            Year ended December 31, (in thousands) ~  ~ ~      CTP-656 external costs ~   ~ : CTP-543 external costs~ v~ B CTP-730 external costs~ ~~ ^*JZP-386 external costs~ N~ )!External costs for other programs~ ~ (0(Employee and contractor-related expenses~ ~ #Facility and other expenses~ n6~  1/'Total research and development expenses~ A~ V$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8=xl`THS;_fth\4=PF0*8X> @      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1)Contractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 0}  $                        %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018 Cash flows                Year ended December 31, (in thousands) ~  ~  ~ ~' Net cash provided by (used in):       Operating activities ~ >H  ~ ;  ~ Vh Investing activities~ ~ N ~   Financing activities~ U~ f  ~  2 0(Net (decrease) increase in cash and cash~ 6~ 6 ~  *  equivalents$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0wk_ Q:.=PF0*8X> @           l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } %} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Contractual obligations                      (in thousands)  Total   Less than  1 to 3  3 to 5   More than       1 year  years  years  5 years' Operating lease obligations (1) ~   ~    $?   $?   $? ' Operating lease obligations (2) ~    ?  ~ ~  ~   ~  %Total contractual obligations~ ~  ~  ~  ~ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|vj^RV6*=PF0*8X> @                 l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 2} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018%INDEX TO FINANCIAL STATEMENTS    / 'Report of independent registered public~ . accounting firm# Consolidated balance sheets~ 2-%Consolidated statements of operations~ 6'and comprehensive income (loss)0(Consolidated statements of stockholders?~ :equity-%Consolidated statements of cash flows~ >2*Notes to consolidated financial statements~ B$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6S|pdXL4L!J>2 =PF0*8X> @ l  =M1<  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U5} $ =                                 %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Basis for Opinion%CONCERT PHARMACEUTICALS, INC.# CONSOLIDATED BALANCE SHEETS             December 31,  ~  ~   % (Amounts in thousands, except!share and per share data)AssetsCurrent assets:!Cash and cash equivalents~ F~ y'Investments, available for sale~ 2 ~ :eInterest receivable~  ~ Accounts receivable~ n~ n1)Prepaid expenses and other current assets~ ~ &Total current assets~  ~ #Property and equipment, net~ !~ ^"Restricted cash~ V~ B Other assets~ ~ Income taxes receivable~ # ? Total assets~ b ~  ,$Liabilities and stockholders? equityCurrent liabilities:Accounts payable~ J ~ .&Accrued expenses and other liabilities~ .C~ 6<D l|pd;x8x-EoDr ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; <  Income taxes payable ~    ? )!!Deferred revenue, current portion!~ !!!~ !R!!"Total current liabilities"~ "d""~ " W"0#(Deferred revenue, net of current portion#~ #n##~ ##0$(Deferred lease incentive, net of current$ $?$$~ $$%portion-&%Deferred rent, net of current portion& &?&&~ &&'Total liabilities'~ '"''~ 'F'(Commitments (Note 11)(((()Stockholders? equity:))))4*,Preferred stock, $0.001 par value per share;* *?** *?*.+&5,000,000 shares authorized; no shares0,(issued and outstanding in 2017 and 2016,- respectively1.)Common stock, $0.001 par value per share;.~ .^..~ .Z.1/)100,000,000 shares authorized; 23,147,77930+and 22,319,516 shares issued and 23,140,378.1&and 22,316,982 outstanding in 2017 and22016 , respectively"3Additional paid-in capital3~ 333~ 3ֶ3,4$Accumulated other comprehensive loss4~ 444~ 445Accumulated deficit5~ 5X55~ 5Z5"6Total stockholders? equity6~ 6B 66~ 6j9627*Total liabilities and stockholders? equity7~ 7b 77~ 7 789$:____________________________1;)Created by Morningstar Document Research.0<(http://documentresearch.morningstar.com/>f 0+c^*\%b{ {oG=PF0*8X> @@<<;;::77776666555544443333....****''''&&&&$$$$####""""!!!!        l  ;Ub  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } :}  $ ;                                 %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Basis for Opinion%CONCERT PHARMACEUTICALS, INC.- %CONSOLIDATED STATEMENTS OF OPERATIONS' AND COMPREHENSIVE INCOME (LOSS)                 Year ended    December 31,~ ~  ~  ~)!(Amounts in thousands, except per share data)Revenue:  4,License and research and development revenue~ ~  ~  f +#Other revenue (Note 14 and Note 13)~ V ? ~   Milestone revenue ? ? ~  B  Total revenue~ N~  ~   Operating expenses:   Research and development~ >~ A ~  V "General and administrative~ nH~ Z ~    Total operating expenses~  ~ 6" ~  V %Income (Loss) from operations~ ~  ~  R Investment income~ ~  ~   Other income (Note 16)~ F8 ?   ? "Interest and other expense~ F ? ~  . 0(Loss on extinguishment of debt (Note 15)~  ?   ? )!Income (Loss) before income taxes~ ~  ~  n D l|pd; CFqY\.r ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : , $(Benefit) Provision for income taxes ~ R   ?  ~  !Net income (loss)!~ !^!!~ !!! ~ ! y! *""Other comprehensive (loss) income:""""" " 0#(Unrealized (loss) income on investments,#~ ###~ #.## ~ # # $ net of tax#%Comprehensive income (loss)%~ %%%~ %%% ~ % y% &&&&&& & 0'(Net income (loss) attributable to common''''''' ' ' ( stockholders: )Basic)~ )n))~ ))) ~ ) y) *Diluted*~ ***~ *** ~ * y* ++++++ + 0,(Net income (loss) per share attributable,,,,, , -to common stockholders: .Basic..@...= ףp=.. . = ףp=?. /Diluted//= ףp=@///= ףp=// / q= ףp?/ 000000 0 01(Weighted-average number of common shares11111 1 820used in net income (loss) per share attributable3to common stockholders: 4Basic4~ 4a44~ 4f[44 ~ 4 J4 5Diluted5~ 5Jn55~ 5f[55 ~ 5 [5 67$8____________________________19)Created by Morningstar Document Research.0:(http://documentresearch.morningstar.com/: _Zu n +f=PF0*8X> @R:: 99 88 555555 444444 ////// ...... ****** )))))) %%%%%% ###### !!!!!!                      l  *  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 2} $ }  } $ } $} &$ *'''''''''' ' ' ' ' '''''''''''''''''''%CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Basis for Opinion%CONCERT PHARMACEUTICALS, INC.0 (CONSOLIDATED STATEMENTS OF STOCKHOLDERS? EQUITY                               Common Stock " Additional paid-in capital . &Accumulated other comprehensive income  Accumulated deficit " Total stockholders? equity   Issued   In Treasury  Amount (in thousands)$Balance at December 31, 2014~  ?~ J  ~  v7 ~ ~  "!"#~ $X&/'Proceeds from public offering of common~ 3 ?~   ~  j ? ?~ v0(stock, net of underwriting discounts andoffering expenses!Exercise of stock options~  ~  ~   ~   ? ?~ 1)Unrealized loss on short-term investments ? ? ?    ?~  ?~ ( Stock-based compensation expense ? ? ?  ~  . ? ?~ .0(Income tax benefit from option exercises ~   ~   Net income ? ? ?    ? ?~ y~ y$Balance at December 31, 2015~ ^Z~  ~ Z  ~  F^~ ~ ښ~ .!Exercise of stock options~ f~  ?  ~  f  ? ?~ f 1)Unrealized gain on short-term investments ? ? ?    ?~ . ?~ .( Stock-based compensation expense ? ? ?  ~  .O ? ?~ .ONet loss ? ? ?    ? ?~ ~ $Balance at December 31, 2016~ \~ ~ Z  ~  ֶ~ ~ Z~ j9!Exercise of stock options~  ~ ~   ~  f ? ?~ f2*Unrealized loss on short-term investments, ? ? ?    ?~  ?~ Dl|pd;= JX'/|K2 '!'"'#'$'%'&'''(')'  net of tax(! Stock-based compensation expense! !?!! !?!! !?! ! ~ ! ҄!! !?!! !?!!~ !҄!"Stock warrants""""""" ~ " "" "?"" "?""~ ""# Net income# #?## #?## #?# #  # ?## #?##~ #^##~ #^#$$Balance at December 31, 2017$~ $i$$~ $"$$~ $^$ $ ~ $ $$~ $$$~ $X$$~ $B $%&$'____________________________1()Created by Morningstar Document Research.0)(http://documentresearch.morningstar.com/th\4=PF0*8X> @Rj))((''$$ $$ $$$$$$## ## ######"" """"""!! !! !!!!!!                              !$%           l  K"  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } mB}  $ K                                 %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Basis for Opinion%CONCERT PHARMACEUTICALS, INC.- %CONSOLIDATED STATEMENTS OF CASH FLOWS                 Year ended    December 31,  ~  ~  ~ ~(in thousands)Operating activities  Net income (loss)~ ^~  ~  y 2*Adjustments to reconcile net income (loss)  ?7to net cash provided by (used in) operating activities:%Depreciation and amortization~ ~   ~  F  ( Stock-based compensation expense~ ҄~ .O ~  . .&Accretion of premiums and discounts on~ j~  ~  .   investments0(Amortization of discount on loan payable~  ? ~  * 0(Amortization of deferred financing costs ? ? ~  v 0(Amortization of deferred lease incentive~ ~  ~  2 !Loss on disposal of asset~ ~   ~   &Loss on extinguishment of debt~ b ?   ? 4,Changes in operating assets and liabilities:  Accounts receivable~ V~  ~   Interest receivable~ ~ F ~  F 1)Prepaid expenses and other current assets~ >~  ~  V Dl|pd; n@13R8 ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ?  Restricted cash ~    ?   ? ! Other assets!~ !!!~ !.!! ~ ! ^! "Accounts payable"~ """~ """ ~ " " .#&Accrued expenses and other liabilities#~ ###~ ### ~ # # $Income taxes receivable$~ $$$ $?$$  $ ?$ %Income taxes payable%~ %%%~ %%% ~ % .% & Deferred rent&~ &j&&~ &6&& ~ & & 'Deferred revenue'~ '''~ '"'' ~ ' ' 0((Net cash provided by (used in) operating(~ (>H((~ (;(( ~ ( Vh( ) activities*Investing activities***** * ++#Purchases of property and equipment+~ +6++~ +++ ~ + r+  ,Purchases of investments,~ ,j,,~ ,",, ~ ,  , !-Maturities of investments-~ -^=--~ -6-- ~ - z - 0.(Net cash (used in) provided by investing.~ ...~ .N.. ~ . . / activities0Financing activities00000 0 1Proceeds from loan, net1~ 1n11 1?11  1 ?1 2Repayment of loan2~ 222 2?22 ~ 2 2 /3'Proceeds from public offering of common3 3?33 3?33 ~ 3 N3 04(stock, net of underwriting discounts and5 commissions/6'Proceeds from exercise of stock options6~ 6f66~ 6f 66 ~ 6 6 17)Income tax benefit from exercise of stock7 7?77 7?77 ~ 7  7 8options(9 Payment of public offering costs9 9?99 9?99 ~ 9 *9 1:)Net cash provided by financing activities:~ :U::~ :f :: ~ : 2: 0;(Net (decrease) increase in cash and cash;~ ;6;;~ ;6;; ~ ; *; < equivalents.=&Cash and cash equivalents at beginning=~ =y==~ =z== ~ = R= > of period2?*Cash and cash equivalents at end of period?~ ?F??~ ?y?? ~ ? z? Dlu]& {W eDmV ]U@ A B C D E F G H I J +@#Supplemental cash flow information:@@@@@ @ "ACash paid for income taxesA~ AAA~ A.AA ~ A A BCash paid for interestB~ B" BB B$?BB ~ B ~B 2C*Purchases of property and equipment unpaidC~ CCC~ CRCC ~ C C D at period end"EIssuance of stock warrantsE~ EEE E$?EE  E $?E FG$H____________________________1I)Created by Morningstar Document Research.0J(http://documentresearch.morningstar.com/]=PF0*8X> @JJ II HH EEEEEE CCCCCC BBBBBB AAAAAA ?????? ====== ;;;;;; :::::: 999999 777777 666666 333333 222222 111111 ...... ------ ,,,,,, ++++++ (((((( '''''' &&&&&& %%%%%% $$$$$$ ###### """""" !!!!!!                     l  d  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } '} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018"3. Fair Value Measurements                    Level 1  Level 2  Level 3  Total December 31, 2017         Cash equivalents:         Money market funds ~ ~   $?   $?  ~ ~ ( Investments, available for sale:   !U.S. Treasury obligations~ ZJ ?   ?  ~ ZJ$Government agency securities~ .i~    ?  ~ k Total~ 62 ~    $?  ~ 4 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2sg[OMG^=PF0*8X> @          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } '} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS                    Level 1  Level 2  Level 3  Total December 31, 2016         Cash equivalents:          Money market funds ~ F   $?   $?  ~ F !U.S. Treasury obligations ?~    ?  ~ ( Investments, available for sale:   !U.S. Treasury obligations~ ʜ~ U   ?  ~ $Government agency securities~ ~    ?  ~ vr Total~ ~ X   $?  ~ "$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4 ocWK?sp1v.o=PF0*8X> @           l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } %} $ } y } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018E=4. Cash, Cash Equivalents and Investments, Available for Sale                      Average   Amortized   Unrealized   Unrealized  Fair   maturity  cost  gains  losses  value December 31, 2017           Cash   ~ 1   $?   $?  ~ 1 Money market funds~ ~ ?    ?~ ~!Cash and cash equivalents~ F $?    $?~ F  !U.S. Treasury obligations184 days~ K $?  ~  ~ ZJ$Government agency securities229 days~ p ?  ~  ~ k'Investments, available for sale~   $?  ~  ~ 2 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6 \PD8,Hg=PF0*8X> @#                      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } %} $ } y } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018E=4. Cash, Cash Equivalents and Investments, Available for Sale                      Average   Amortized   Unrealized   Unrealized  Fair   maturity  cost  gains  losses  value December 31, 2016           Cash   ~    $?   $?  ~  Money market funds~ F ?    ?~ F!U.S. Treasury obligations31 days~  ?    ?~ !Cash and cash equivalents~ y $?    $?~ y  !U.S. Treasury obligations125 days~ ~   ~  ~ $Government agency securities140 days~ r~   ~  ~ vr'Investments, available for sale~ Ve~   ~  ~ :e$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 \PD8,Hg,=PF0*8X> @:'                        l   %  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 7} $ } 6}  $                          %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018!6. Property and Equipment              Estimated useful life   December 31,   December 31,    (in years) ~  ~  Laboratory equipment ~  ~ )  ~ B! 0 (Computer, telephone and office equipment ~  ~ N  ~ > Software~ ~ ~  Leasehold improvements5-Lesser of useful life or remaining lease term~ ^f~ Rf ~ ~ ΍ 6.Less accumulated depreciation and amortization~ ~  ~ !~ ^" $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4kth\PKcO,=PF0*8X> @                l  [5  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and EquipmentNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 1} $                         %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20181)7. Accrued Expenses and Other Liabilities             December 31,   December 31,  ~  ~ + #Accrued professional fees and other ~    ~  * "Employee compensation and benefits ~ +  ~ j )!Research and development expenses~ &~ 1)Deferred lease incentive, current portion~ ~ &Deferred rent, current portion~ ~ ~ .C~ 6<$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pdXL@@KQwkC=PF0*8X> @         l  F  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $4}  $                           %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS                Year ended December 31,  ~  ~  ~ ~  - %(in thousands, except per share data). &Weighted average fair value of options  Gz@   ףp= $@    ףp=$@ granted, per option2*Aggregate grant date fair value of options~ a~ H ~  :6 vested during the year3+Total cash received from exercises of stock~ f~ f  ~   options.&Total intrinsic value of stock options~ ҇~ " ~    exercised$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6ocWK?hN,p=PF0*8X> @            l  V  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U} $ }  } $} $ }  } $} $ }  } $                       %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS             Year ended December 31,  ~  ~  ~ ~ Expected volatility  S@ %  (\S@ %  QXR@ %  Expected term   6.0 years    6.0 years    6.0 years Risk-free interest rate(\@ %(\? % ףp= ?  %Expected dividend yield ? % ? % ?  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.ocWK?2Ny=PF0*8X> @:       l  Nl  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $4} $ } y} $ } } $ } } $                              %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS                 Number of  Weighted  Weighted   Aggregate    Option Shares  Average  Average   Intrinsic      Exercise   Remaining  Value       Price per   Contractual Share  Term  (In years)  (In thousands)( Outstanding at December 31, 2016~ K{G$@   Granted~ rA&@    Exercised~ frQ @   Forfeited or expired~ r(\(@   ( Outstanding at December 31, 2017~ _&@ = ףp=@ ~   ( Exercisable at December 31, 2017~ bQ8$@ \(\@ ~   3+Vested and expected to vest at December 31,~ >Qk&@  ףp= @ ~  } 2017 (1)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/< ocWK?W"b=PF0*8X> @           l  Z|  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } '}  } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS          Number of  Weighted   RSU Shares  Average     Grant Date Fair Value    ( Outstanding at December 31, 2016 ? $? Granted~ = ףp+@ Released ? $? Forfeited~ = ףp+@( Outstanding at December 31, 2017~ Ғ= ףp+@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4ocWK?i} h=PF0*8X> @j       l  s  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)NOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 0.}  $                      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018( Stock-based compensation expense               ' For the Year Ended December 31,  ~  ~  ~ ~ Research and development ~ 9  ~ !  ~  " General and administrative ~ J  ~ -  ~   .&Total stock-based compensation expense~ ҄~ .O ~  . $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|ymaUIjz>2&=PF0*8X> @           l  8ު  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } I;}  $ 8                                 %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS             ' For the Year Ended December 31, ~  ~  ~ ~ Basic Earnings per Share0 ((in thousands, except per share amounts)  Numerator:     Net income (loss)~ ^~ ~  y ,$Income attributable to participating~  ?  ? securities - basic91Income (loss) attributable to common stockholders~ n~ ~  y - basic  Denominator: +#Weighted average shares outstanding~ a~ f[~  J .&Net income (loss) per share applicable@= ףp= = ףp=? &to common stockholders - basic "Diluted Earnings per Share  Numerator: Net income (loss)~ ^~ ~  y ,$Income attributable to participating~  ?  ? securities - diluted91Income (loss) attributable to common stockholders~ ~ ~  y  - dilutedD locWK?x*iKMdNc ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7       ! Denominator:!!!!! +"#Weighted average shares outstanding~ "a""~ "f[""~ " J" ####### # $Dilutive impact from:$$$$$$ $ % Stock options~ % %% %?%%~ % F% &Warrants &?&& &?&&~ & *& 'Restricted stock units~ ''' '?'' ' ?' -(%Weighted average shares outstanding -~ (Jn((~ (f[((~ ( [( )diluted.*&Net income (loss) per share applicable*= ףp=@***= ףp=*** q= ףp?* (+ to common stockholders - diluted,,,,,, ,-$Anti-dilutive potential common stock----- 1.)equivalents excluded from the calculation'/of net income (loss) per share:0 Stock options~ 000~ 0 00~ 0 0 1Restricted stock units~ 1b11 1?11 1 ?1 2Warrants 2?22~ 222~ 2 2 34$5____________________________16)Created by Morningstar Document Research.07(http://documentresearch.morningstar.com/4 do|~0PqrfZ2=PF0*8X> @;77 66 55 222222 111111 000000 ****** (((((( '''''' &&&&&& %%%%%% """"""             l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 2} $ }  } $} $ }  } $} $ }  } $                            %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS             Year ended December 31,  ~  ~  ~ ~) !Federal statutory income tax rate ~ v % ~  % ~ z % State income taxes  ffffff %  @ %  333333 %%Change in valuation allowanceG@ %fffff&D %L@@  %2*Research and development and other credits@ %@ %333333@  %Permanent items? %~  %333333ӿ  %Alternative minimum tax ? % ? %333333  % Other ? %333333ӿ %  %Federal rate change333333" % ? % ?  %!Effective income tax rate333333? % ? %333333  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 ocWK?2G^;Z=PF0*8X> @:       l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 1} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS           December 31, ~  ~ (  Net operating loss carryforwards~ Z  ~ H  Deferred revenue~ *  ~ = 1)Research and development and other credit~ ^~  carryforwards Other~ ;~ .<~ ~ >kValuation allowance~ ~ ƔNet deferred tax assets $? $?$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6ocWK?J15=PF0*8X> @        l  j  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } I"} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20182*NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        Base rent obligations At December 31, 2017 ~ ~  ~ ~ b+~ ~ >%~ ~ .~ ~ j/Greater than 5 years~ ;$Total minimum lease payments~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6CocWK?vN&ZNB=PF0*8X> @Z    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } }  } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018F>15. Loan Payable and Warrant to Purchase Redeemable Securities    Expected volatility = ףpmR@ % Expected term (in years)~   Risk-free interest rate ? % Expected dividend yield ? %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h[OC7+I =PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to 18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } -} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20187/18. Quarterly Financial Information (unaudited)                    Three Months Ended    March 31,  June 30,   September 30,   December 31,  ~  ~  ~  ~   - %(in thousands, except per share data) (unaudited)Revenue~ R~ > ~    ~ 2Operating expenses~ ~  ~    ~ 6%Income (Loss) from operations~ -~ >5 ~     ~ 8#Other income (expense), net~ &~ : ~  &  ~ A,$(Provision) Benefit for income taxes ? ? ~    ~ &Net income (loss)~ /~ v4 ~    ~ :)!Net income (loss) per share?basic333333(\  q= ףp@  p= ףп-%Net income (loss) per share - diluted333333(\  (\@  p= ףп$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<- j^RF:n8. UZl=PF0*8X> @r.                 l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 0.} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20187/18. Quarterly Financial Information (unaudited)                    Three Months Ended    March 31,  June 30,   September 30,   December 31,  ~  ~  ~  ~   - %(in thousands, except per share data) (unaudited)Revenue~ ~  ~  j  ~ VOperating expenses~ :~ 2 ~    ~ 6Loss from operations~ %~ + ~  L  ~ "BOther income, net~ z~  ~    ~ Net loss~ "'~ - ~  N  ~ C.&Net loss per share - basic and diluted)\(333333  RQ  HzG$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8O j^RF:n8. U @2&               l  "V*/+  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } $ } $} $ } U5 "     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018( EXECUTIVE OFFICERS AND DIRECTORS            Name  Age   Position(s) Executive Officers     Roger D. Tung, Ph. D. ~   . &President and Chief Executive Officer,Director James V. Cassella, Ph.D.~ !Chief Development Officer Nancy Stuart~ Chief Operating Officer Marc Becker~ Chief Financial OfficerLynette Herscha, J.D.~ General CounselNon-Employee DirectorsRichard H. Aldrich~ 4,Director, Chairman of the Board of Directors"Thomas G. Auchincloss, Jr.~ Director Ronald W. Barrett, Ph.D.~ Director Meghan FitzGerald, Ph.D.~ DirectorChristine van Heek~ DirectorPeter Barton Hutt, LL.M~ NDirectorWilfred E. Jaeger, M.D.~ DirectorWendell Wierenga, Ph.D.~ Director$____________________________D# lymaUIw)TlV| @"!!   l   E  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $4} $ } } $ }  } $ } $}  $ } y} $ } m} $ }  } $ }  } $ } y} $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018'2017 Summary Compensation Table                         Name  Year  Salary  Bonus   Option awards  Stock awards ($)   Non-equity   All other   Total ($)    ~  ~   ($) (1)     incentive plan   compensation                  compensation  ($) (5)                 ($) (4)Roger D. Tung, Ph.D.~ ~ j ? ~  U[    1,109,600 (2)~ (~ ʚ~ g-%President and Chief Executive Officer~ ~  ? ~  &Cv    ?~ j4 ~ r~  James V. Cassella, Ph.D.~ ~  ? ~      832,200 (3)~ Vi ~ ~ w3+Senior Vice President and Chief Development~ ~  ? ~  v"    ?~ ~ ~ nCOfficer Nancy Stuart~ ~ N ? ~      832,200 (3)~ j. ~ ʚ~ vChief Operating Officer~ ~ 2| ? ~  "7    ?~ ~ r~ ?W$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/84znbVJ*-6cr}qe==PF0*8X> @              l  V  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } %} $ } y#} $ } y#      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018/'Narrative to Summary Compensation Table     ' Achillion Pharmaceuticals, Inc. ! Genocea Biosciences, Inc. % Paratek Pharmaceuticals, Inc.     Agenus, Inc.  Geron Corporation ! Sangamo Biosciences, Inc.   !Akebia Therapeutics, Inc.GlycoMimetics, Inc.!Selecta Biosciences, Inc. Ardelyx, Inc. Ignyta, Inc. Trevena, Inc.Cytokinetics, Inc.$Inovio Pharmaceuticals, Inc. Xencor, Inc.Edge Therapeutics, Inc.%Karyopharm Therapeutics, Inc.Ziopharm Oncology, Inc. Epyzime, Inc.!Mirati Therapeutics, Inc. Zogenix, Inc.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<rfZNBuQ:o3=PF0*8X> @ l  '/xZ{  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } }  } $ }  } $ } U}  } $ }  } $ } } $ } } y} $ }  } $ }  } y} $ '     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018B:111Outstanding Equity Awards at 2017 Fiscal Year End Table                      Options Awards   Stock Awards Name Number of securities Number of securities  Option Option 5 -Number of units of stock that have not vested 0 (Market value of units of stock that have/ 'Equity incentive plan awards: Number of / 'Equity incentive plan awards: Market or  underlying unexercised underlying unexercised  exercise  expiration  (#)  not vested ($) (9)/ 'unearned units that have not vested (#) . &payout value of unearned shares, units  options (#) exercisable! options (#) unexercisable   price ($) date         0 (or other rights that have not vested ($)Roger D. Tung, Ph.D.~  ?~ RQ@ 12/19/2018    ~ R ?~ p= ף@ 12/10/2019    ~ J ?~ RQ@ 12/14/2020    ~ :n ?~  @ 12/15/2021    ~  ~ ~  @ 6/10/2024    ~ ~ &~ 0@1/7/2026    ~ I~  ~ q= ף%@1/4/2027     ~  q ~  ~  (?~ q~ ~ (? James V. Cassella, Ph.D.~ ~ ~ Q,@3/5/2025    ~ U~ v~ 0@1/7/2026    ~ ~ x~ q= ף%@1/4/2027     ~  " ~  ~   G~ b~ ~ J Nancy Stuart~  ?~ RQ@ 12/19/2018    ~ B ?~ p= ף@ 12/10/2019    ~ K ?~ RQ@ 12/14/2020    ~ Y ?~  @ 12/15/2021    ~ 2W~ R~  @ 06/10/2024    ~ "~ "~ 0@ 01/07/2026    Dl_SG;/?~A3^ 7_s=h !"#$%& ~  ~ x ~  q= ף%@   01/04/2027       !!!!!!! ~ ! "! ~ ! ~ !  G!~ !b!~ !~ !J!"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/x*RF:=PF0*8X> @&&%%$$                   l   3  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards atDirector CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 0} $ }  } $ }  } $ }  } $ } y} $ }  } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018kcPayments and benefits provided upon a qualifying termination in connection with a change of control                 Name  Cash  Bonus  COBRA  Value of   Total ($)    Severance  ($) (2)   Continuation   Accelerated   ($) (1)     ($) (3) (  Vesting of Stock Options ($) (4) Roger D. Tung, Ph.D.          0(Qualifying termination not in connection~ y' ?~ 5    ?  ~ ) with a change of control,$Qualifying termination in connection~ ^/~ R~ 2  ~  ޅ  ~ :- with a change of control James V. Cassella, Ph.D.   0(Qualifying termination not in connection~  ?~ J    ?  ~  with a change of control,$Qualifying termination in connection~ ~ J ~ J  ~  a  ~ *0 with a change of control Nancy Stuart   0(Qualifying termination not in connection~ N ?~ n    ?  ~   with a change of control,$Qualifying termination in connection~ N~  ~ n  ~  Y  ~ } with a change of control$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/Dl6*F f  VfBT0$=PF0*8X> @z          l  p  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } 6} $ }  } $ }  } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Director Compensation               Annual Member Fee ($)  Chairman Annual Fee ($) Board of Directors ~ q  ~   Audit Committee ~ 2u  ~ b Compensation Committee~ "N~ B5-Nominating and Corporate Governance Committee~ .~ bm$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.xl`T\X=PF0*8X> @*   l  1  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director Compensation!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } $ }  } $ }  } $ }  } $                            %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Director Compensation                  Name  Fees earned or  Option awards ($)(1)   Total ($)   paid in cash ($) Richard H. Aldrich ~ "  ~   ~ <  "Thomas G. Auchincloss, Jr.~ 7~ ~ B  Ronald W. Barrett, Ph.D.~ ~ ~ "s  Meghan FitzGerald, Ph.D.~ ~ ~ % Christine van Heek~ ~ ~ L Peter Barton Hutt~ J~ ~ ] Wilfred E. Jaeger, M.D.~ ~ ~ 2 Wendell Wierenga, Ph.D.~ B|~ ~  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8} xl`TA}^4(=PF0*8X> @:       l  &8F  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } U5} $ } y} $ } U} $ &     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018kcItem 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Mat        Name of beneficial owner   Number of   Percentage   shares   of shares    beneficially   beneficially   owned  owned5% Stockholders.&Entities affiliated with BVF, Inc. (1)~ 9x!@ %3+Entities affiliated with BlackRock Inc. (2)~ m@ % Ingalls & Snyder LLC (3)~ VQ@ %4,Entities affiliated with GlaxoSmithKline (4)~ Hffffff@ %( Executive Officers and Directors Roger D. Tung, Ph.D. (5)~ VAF~  %$James V. Cassella, Ph.D. (6)~   *Nancy Stuart (7)~ r? %Richard H. Aldrich (8)~ ? %!Thomas G. Auchincloss (9)~ S *%Ronald W. Barrett, Ph.D. (10)~  *%Meghan FitzGerald, Ph.D. (11)~ y *Christine van Heek (12)~ Y *$Peter Barton Hutt, LL.M (13)~  *$Wilfred E. Jaeger, M.D. (14)~  *$Wendell Wierenga, Ph.D. (15)~ v! *D l6*Kf!A^v !"#$%4 ,All current executive officers and directors ~    "@ %$!as a group (13 persons) (16)"$#____________________________1$)Created by Morningstar Document Research.0%(http://documentresearch.morningstar.com/dwOC=PF0*8X> @Z %%$$##         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } a} $                       %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20187/Item 14. Principal Accountant Fees and Services           Fee Category ~  ~  Audit Fees (1) ~ "  ~   Audit-Related Fees  ?   ?   Tax Fees (2) ~    ~ "Q All Other Fees (3)~ B~ B Total Fees~ %~ J$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.j^RF:PxlD=PF0*8X> @z         l  j  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } I } $ } > j     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Part IV Exhibit Index       Exhibit   Description number  @-%Restated Certificate of Incorporation4,of the Registrant (incorporated by reference2*to Exhibit 3.1 to the Registrant?s current/'report on Form 8-K (File No. 001-36310)0(filed with the SEC on February 20, 2014) @5-Amended and Restated Bylaws of the Registrant-%(incorporated by reference to Exhibit.&3.2 to the Registrant?s current report3+on Form 8-K (File No. 001-36310) filed with%the SEC on February 20, 2014)ffffff @0(Amendment to Amended and Restated Bylaws4,of the Registrant (incorporated by reference3+to Exhibit 3.3 to the Registrant's previous2*Annual Report on Form 10-K, filed with theSEC on March 6, 2017)DlznU1 ^u)q's!4 !"#$%&'()*+,-./0123456789:;<=>? ffffff@ . &Specimen certificate evidencing shares!!2!*of common stock (incorporated by reference""7"/to Exhibit 4.1 to the Registrant?s registration##4#,statement on Form S-1 (File No. 333-193335),$$/$'filed with the SEC on February 3, 2014)%%&333333$@&/&'Third Amended and Restated Registration''3'+Rights Agreement, dated as of June 1, 2009,((-(%as amended (incorporated by reference))8)0to Exhibit 10.1 to the Registrant?s registration**4*,statement on Form S-1 (File No. 333-193335),++/+'filed with the SEC on January 13, 2014),,-ffffff$@-:-2Warrant to purchase shares of Series C Convertible..0.(Preferred Stock issued by the Registrant//./&to Hercules Technology Growth Capital,0020*Inc. (incorporated by reference to Exhibit11-1%10.2 to the Registrant?s registration2242,statement on Form S-1 (File No. 333-193335),33/3'filed with the SEC on January 13, 2014)44510.3 #5.5&Amended and Restated 2006 Stock Option6606(and Grant Plan, as amended (incorporated77870by reference to Exhibit 10.3 to the Registrant?s8808(registration statement on Form S-1 (File99:92No. 333-193335), filed with the SEC on January 13,::~ :z;;<10.4 #<0<(Form of Incentive Stock Option Agreement==<=4under 2006 Stock Option and Grant Plan (incorporated>>8>0by reference to Exhibit 10.4 to the Registrant?s??0?(registration statement on Form S-1 (FileDj lbt\ slz,H0@x`@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_@@6@.No. 333-193335), filed with the SEC on JanuaryAAA 13, 2014)BBC10.5 #C3C+Form of Nonstatutory Stock Option AgreementDD<D4under 2006 Stock Option and Grant Plan (incorporatedEE8E0by reference to Exhibit 10.5 to the Registrant?sFF0F(registration statement on Form S-1 (FileGG6G.No. 333-193335), filed with the SEC on JanuaryHHH 13, 2014)IIJ10.6 #J/J'2014 Stock Incentive Plan (incorporatedKK8K0by reference to Exhibit 10.6 to the Registrant?sLL0L(registration statement on Form S-1 (FileMM7M/No. 333-193335), filed with the SEC on FebruaryNNN3, 2014)OOP10.7 #P0P(Form of Incentive Stock Option AgreementQQ5Q-under 2014 Stock Incentive Plan (incorporatedRR8R0by reference to Exhibit 10.7 to the Registrant?sSS0S(registration statement on Form S-1 (FileTT7T/No. 333-193335), filed with the SEC on FebruaryUUU3, 2014)VVW10.8 #W3W+Form of Nonstatutory Stock Option AgreementXX5X-under 2014 Stock Incentive Plan (incorporatedYY8Y0by reference to Exhibit 10.8 to the Registrant?sZZ0Z(registration statement on Form S-1 (File[[7[/No. 333-193335), filed with the SEC on February\\\3, 2014)]]^10.9 #*^3^+Form of Employment Agreement by and between__0_(the Registrant and each of its executiveD lih4AZg;#})^F`abcdefghi```officersaab10.10*b1b)Lease Agreement, dated as of December 21,cc/c'2017, by and between the Registrant anddd"dHCP/King Hayden Campus LLCef$g____________________________1h)Created by Morningstar Document Research.0i(http://documentresearch.morningstar.com/i=PF0*8X> @"iihhgg l  .  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } y } $ } 7 .     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018Part IV    31.2* - %Chief Financial Officer?Certification  4 ,pursuant to Rule 13a-14(a) of the Securities  1 )Exchange Act of 1934, as adopted pursuant  0 (to Section 302 of the Sarbanes-Oxley Actof 200232.1**-%Chief Executive Officer?Certification6.pursuant to 18 U.S.C. Section 1350, as adopted5-pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2**-%Chief Financial Officer?Certification6.pursuant to 18 U.S.C. Section 1350, as adopted5-pursuant to Section 906 of the Sarbanes-Oxley Act of 2002101.INS*XBRL Instance Document101.SCH*/'XBRL Taxonomy Extension Schema Document101.CAL*4,XBRL Taxonomy Extension Calculation LinkbaseDocumentDwlznb>Su# @--,,++ l  -  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } $ } -      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/201810. Miscellaneous.               Very truly yours,         Roger D. Tung-%President and Chief Executive OfficerAgreed and Accepted: Signature:[Name] Date:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<{ocWn2dJ=PF0*8X> @ l  2?E  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous 234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } $4} }  2     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018LEASE SUMMARY SHEET     Rent Commencement Dates:0 (Base Rent Commencement Date : The later 1 )of: (i) January 1, 2019, or (ii) the Term  Commencement Date. 3 +Additional Rent Commencement Date (Tenant?s7/Share of Operating Costs, Taxes, & Utilities) :3+The later of: (i) November 1, 2018, or (ii)#the Term Commencement Date.Expiration Date:7/Ten (10) years after the Base Rent Commencement7/Date, except that if the Base Rent Commencement80Date does not occur on the first day of calendar1)month, then the Expiration Date shall the3+last day of the calendar month in which the7/tenth anniversary of the Base Rent Commencement Date occurs.Extension Term(s):7/Subject to Section 1.2 below, two (2) extension)!term(s) of five (5) year(s) each. Landlord?s Contribution:Up to $4,996,980.00.Permitted Uses:.&Subject to Legal Requirements, general4,office, research, development and laboratory1)use, and other ancillary uses (including,2*but not limited to, vivarium uses) relatedto the foregoing.D lznbV&c c }<5k' !"#$%&'()*+,-./01  Base Rent : PERIOD ANNUAL BASE RENT MONTHLY PAYMENT!3!+Commencement Date to day prior to Base Rent !$-0- !$-0-""Commencement Date## Rent Year 1~ #p#(\m= A$$ Rent Year 2*~ $ޅ$(\O A%% Rent Year 3%3333FxFA%\ A&& Rent Year 4&333$GA&QA'' Rent Year 5'333sGA'= ףA(( Rent Year 6(ffffHA(q^A)) Rent Year 7)L @1100//     l  6-W]  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } <} I; 6     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018234LIST OF EXHIBITS    EXHIBIT 1A9 1LEASE PLAN - PRIME PREMISES AND COMMON MECHANICAL  CLOSETS  EXHIBIT 1B1 )LEASE PLAN - PH SYSTEM AREA AND PH SYSTEM  ROOM EXHIBIT 1C,"LEASE PLANS ? RFO PREMISES SHEET 10(LEASE PLAN ? RFO PREMISES (SECOND FLOOR)SHEET 2SHEET 3/'LEASE PLAN ? RFO PREMISES (THIRD FLOOR) EXHIBIT 1D,$LEASE PLAN ? NON-HM STORAGE PREMISES LEASE PLAN ? STROBIC FAN EXHIBIT 2 LEGAL DESCRIPTION - LAND EXHIBIT 37/LEASE PLAN ? CURRENT PARKING AREAS AND NITROGENPREMISES EXHIBIT 4 WORK LETTER EXHIBIT 4-1'INITIAL PLAN OF LANDLORD?S WORK EXHIBIT 4-2EQUIPMENT LIST EXHIBIT 4-3-%LANDLORD/TENANT RESPONSIBILITY MATRIX EXHIBIT 55-EXISTING BASE BUILDING SYSTEMS AND CAPACITIES EXHIBIT 6 FORM OF LETTER OF CREDIT EXHIBIT 6-1.&ELEVATION SHOWING LOCATION OF TENANT?S MONUMENT SIGNDlznbV>e(wU`@Y  !"#$%&'()*+,-./012345  EXHIBIT 7 LANDLORD?S SERVICES! EXHIBIT 8)!!TENANT?S HAZARDOUS MATERIALS LIST" EXHIBIT 9-1&"BUILDING RULES AND REGULATIONS# EXHIBIT 9-23#+CONSTRUCTION BUILDING RULES AND REGULATIONS$ EXHIBIT 10*$"TENANT WORK INSURANCE REQUIREMENTS% EXHIBIT 11%ADDITIONAL PROVISIONS& EXHIBIT 12,&$PLAN--LOADING DOCKS, RECEIVING AREA,'-'%FREIGHT ELEVATORS, AND NON-HM STORAGE((PREMISES) EXHIBIT 13#)LIST OF REQUIRED REMOVABLES* EXHIBIT 14-10*(MASTER DEED OF THE HAYDEN SCIENCE CENTER++ CONDOMINIUM, EXHIBIT 14-22,*DECLARATION OF TRUST OF THE HAYDEN SCIENCE--CENTER CONDOMINIUM. EXHIBIT 14-3-.%THE HAYDEN SCIENCE CENTER CONDOMINIUM/ /PLANS0012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/0&I:T1pS;/#=PF0*8X> @554433 l  8kpfx  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $} 0} } $ 8     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20185TABLE OF CONTENTS    ~ . &LEASE GRANT; TERM; APPURTENANT RIGHTS;~     EXCLUSIONS ?  Lease Grant~   333333? Extension Terms~  ?Appurtenant Rights~  ffffff?Tenant?s Access~ ?'No recording // Notice of Lease~ ? Exclusions~ 333333? Acid Neutralization Tank~ ? Nitrogen Tank~ "ffffff?Non-HM Storage Premises~ &~  #RIGHTS RESERVED TO LANDLORD~ *@!Additions and Alterations~ *@!Additions to the Property~ *ffffff@$Name and Address of Building~ .333333@Landlord?s Access~ .@!Pipes, Ducts and Conduits~ 2@!Common Mechanical Closets~ 2@Minimize Interference~ 6~ +#CONDITION OF PREMISES; CONSTRUCTION~ 6@Condition of Premises~ 6 @Landlord?s Work~ 6D l{ocW'h!9bs"4? !"#$%&'()*+,-./01234567 ffffff @0 (Tenant?s Remedies in the Event of Delays~ : !!!in Term Commencement Date~ ""USE OF PREMISES~ ">" #(a)#Permitted Uses~ #>#$@$Prohibited Uses~ $>$%333333@!%Transportation of Animals~ %B%&@& MWRA Permit~ &F&'@-'%Parking and Traffic Demand Management~ 'F'( (Plan)ffffff@)Vivarium~ )F)~ **RENT; ADDITIONAL RENT~ *F*+ffffff@+ Base Rent~ +F+,@,Operating Costs~ ,J,-333333@ -Taxes~ -V-.@. Late Payments~ .Z./@0/(No Offset; Independent Covenants; Waiver~ /^/0ffffff@0 Audit Right~ 0b01@1Survival~ 1b1~ 22INTENTIONALLY OMITTED~ 2f234$5____________________________16)Created by Morningstar Document Research.07(http://documentresearch.morningstar.com/4o,QU G_=PF0*8X> @776655 l  9SY  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $} $4} $} $ 9     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20185TABLE OF CONTENTS    ~  LETTER OF CREDIT~ f  ffffff@ Amount~ f  @3 +Application of Proceeds of Letter of Credit~ f  333333@$ Transfer of Letter of Credit~ j @)!Cash Proceeds of Letter of Credit~ j@/'Return of Security Deposit or Letter of~ jCreditffffff@.&Reduction of the Cash Security Deposit~ j and/or Letter of Credit.~ "INTENTIONALLY OMITTED~ n~ &&UTILITIES, LANDLORD?S SERVICES~ n333333"@ Electricity~ nffffff"@ Water~ r"@ Gas~ r"@Other Utilities~ r#@0(Interruption or Curtailment of Utilities~ r333333#@Landlord?s Services~ v~ *MAINTENANCE AND REPAIRS~ v333333$@)!Maintenance and Repairs by Tenant~ vffffff$@+#Maintenance and Repairs by Landlord~ v$@/'Accidents to Sanitary and Other Systems~ z$@#Floor Load--Heavy Equipment~ zD l{ocW'B6Ao4BC !"#$%&'()*+,-./012345678 %@ Premises Cleaning~ z !333333%@! Pest Control~ !~!"ffffff%@"Service Interruptions~ "~"~ #..#&ALTERATIONS AND IMPROVEMENTS BY TENANT~ ##$333333&@-$%Procedures for Performing Alterations~ $$%ffffff&@(% Landlord Approval of Alterations~ %%&&@(& Removal of Alterations by Tenant~ &&'&@' After-Hours~ ''('@(Harmonious Relations~ (()333333'@ )Liens~ ))*ffffff'@*General Requirements~ **~ +2+SIGNAGE~ ++,333333(@, Restrictions~ ,,-ffffff(@-Monument Signage~ --.(@+.#Building Directory/Premises Signage~ ..~ /6-/%ASSIGNMENT, MORTGAGING AND SUBLETTING~ //0333333*@#0Landlord?s Consent Required~ 001ffffff*@"1Landlord?s Recapture Right~ 112*@'2Standard of Consent to Transfer~ 223*@!3Listing Confers no Rights~ 3345$6____________________________17)Created by Morningstar Document Research.08(http://documentresearch.morningstar.com/6s&o|0l(,0=PF0*8X> @887766 l  9B  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } 7} $} $ 9     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20185TABLE OF CONTENTS     +@, $Profits In Connection with Transfers~   333333+@ Prohibited Transfers~   ffffff+@- %Exceptions to Requirement for Consent~  ~ :/ 'INSURANCE; INDEMNIFICATION; EXCULPATION~  333333,@Tenant?s Insurance~ ffffff,@Indemnification~ ,@Property of Tenant~ ,@.&Limitation of Landlord?s Liability for~ Damage or Injury-@-%Waiver of Subrogation; Mutual Release~ 333333-@*"Tenant?s Acts--Effect on Insurance~ ffffff-@Landlord?s Insurance~ ~ >CASUALTY; TAKING~ 333333.@Damage~ ffffff.@Termination Rights~ .@Rent Abatement~ .@!Taking for Temporary Use.~ /@Disposition of Awards~ ~ BESTOPPEL CERTIFICATE~ ~ FHAZARDOUS MATERIALS~ 1@ Prohibition~ 3333331@Environmental Laws~ D l{ocW'"}6f cQk$ !"#$%&'()*+,-./012345678 L1@" Hazardous Material Defined~  !ffffff1@!Chemical Safety Program~ !!"1@"Testing~ ""#1@#Indemnity; Remediation~ ##$333331@$ Disclosures~ $$%1@%Removal~ %%&fffff1@6&.Landlord Obligations with respect to Hazardous~ &&'' Materials~ (J(RULES AND REGULATIONS~ (()2@)Rules and Regulations~ ))*3333332@*Energy Conservation~ **+L2@+ Recycling~ ++~ ,N,LAWS AND PERMITS~ ,,-3@-Legal Requirements~ --~ .R.DEFAULT~ ../4@/Events of Default~ //03333334@0Remedies~ 001L4@1Damages - Termination~ 112ffffff4@/2'Landlord?s Self-Help; Fees and Expenses~ 2234@.3&Waiver of Redemption, Statutory Notice~ 3344and Grace Periods5$6____________________________17)Created by Morningstar Document Research.08(http://documentresearch.morningstar.com/6o_ P3cUK"=PF0*8X> @887766 l  1^"  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } 1} $} $ 1     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20185TABLE OF CONTENTS     4@) !Landlord?s Remedies Not Exclusive~   333334@  No Waiver~   4@' Restrictions on Tenant?s Rights~   fffff4@ Landlord Default~  ~ V0(SURRENDER; ABANDONED PROPERTY; HOLD-OVER~ 5@ Surrender~ 3333335@Abandoned Property~ L5@Holdover~ ffffff5@ Warranties~ ~ ZMORTGAGEE RIGHTS~ 6@ Subordination~ 3333336@Notices~ L6@Mortgagee Consent~ ffffff6@Mortgagee Liability~ ~ ^QUIET ENJOYMENT~ ~ bNOTICES~ ~ f MISCELLANEOUS~ 9@ Separability~ 3333339@Captions~ L9@Broker~ ffffff9@Entire Agreement~ 9@ Governing Law~ De l{ocW'6QAt)j& !"#$%&'()*+,-./0 9@# Representation of Authority~  !333339@1!)Expenses Incurred by Landlord Upon Tenant~ !!""Requests#9@#Survival~ ##$fffff9@ $Limitations of Liability~ $$%9@%Binding Effect~ %%&\(9@*&"Landlord Obligations upon Transfer~ &&'Q9@'No Grant of Interest~ ''(zG!9@(Financial Information~ (()p= #9@&)OFAC Certificate and Indemnity~ ))*fffff&9@*Confidentiality~ * *+)\(9@+ Force Majeure~ + +,-$.____________________________1/)Created by Morningstar Document Research.00(http://documentresearch.morningstar.com/&|@L,Vc uiA=PF0*8X> @00//.. l  (  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3)!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } + (     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018 24. NOTICES.   If to Landlord:" HCP/King Hayden Campus LLC " c/o King Street Properties  200 Cambridge Park Drive  Cambridge, MA 02140#Attention: Stephen D. LynchWith a copy to:Goulston & Storrs PC400 Atlantic AvenueBoston, MA 02110Attention: King Street if to Tenant:%Concert Pharmaceuticals, Inc.65 Hayden AvenueLexington, MA 02421"Attention: General CounselWith a copy to:Ropes & Gray LLPPrudential Tower800 Boylston StreetDlui]EwD,X@(aI1 !"#$%&'  Boston, MA 021909-3600!,!$Attention: Christopher F. Dunn, Esq.""#$$%____________________________1&)Created by Morningstar Document Research.0'(http://documentresearch.morningstar.com/~rf>=PF0*8X> @''&&%% l  5o  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICESLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $ } -} $ } y } } 8 5     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018-%LANDLORD/TENANT RESPONSIBILITY MATRIX      2 *Landlord/Tenant Operational Responsibility    Matrix% 65 Hayden Ave., Lexington, MA        Landlord Tenant Notes UtilitiesBuilding Electricity X7/Tenant premises will be separately sub-metered.Exterior lot lighting X Gas XWater and Sewer X$Water and Sewer - Irrigation X'Telephone Loading Dock Intercom X-%Telephone - Elevator/Fire Alarm Panel X JanitorialContract - Common Areas X"Contract - Tenant Premises X%Supplies/other - Common Areas X( Supplies/other - Tenant Premises XInterior Window Washing XExterior Window Washing XD lth\PD7CA8bh6 !"#$%&'()*+,-./01234 + #Trash and Recycling (non-hazardous)  X / 'Landlord will provide a dumpster at the!!!!!&!loading dock for tenant's use."#"Biohazard Disposal Services"" "X"######$$Roads and Grounds$$$$%%Landscape Maintenance% %X%%&&Parking Lot Maintenance& &X&&'' Snow removal' 'X''((Sidewalk/Other( (X(())Common Maintenance) )X))******++Life Safety Systems++++,',Fire & Sprinkler Annual Testing, ,X,,- -Fire Alarm System Maint.- -X--.$.Generator PM - Base Building. .X../"/TT Supplemental Generators// /X/01$2____________________________13)Created by Morningstar Document Research.04(http://documentresearch.morningstar.com/.Dm[D=2l =PF0*8X> @2443322    l  0| !  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY M!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } $ } *} $ } $} $ 0     %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018-%LANDLORD/TENANT RESPONSIBILITY MATRIX       $ Extinguishers - Common Areas  X   ' Extinguishers - Tenant Premises   X         Repairs & Maintenance    Electrical R&M - Common X( Electrical R&M - Tenant Premises X( Bulbs and Ballast - Common Areas X+#Bulbs and Ballast - Tenant Premises X$Elevator Contract and Maint. XHVAC Repairs/Supplies X*"HVAC - Supplemental Units/Supplies X#Plumbing R&M - Common Areas X&Plumbing R&M - Tenant Premises X!Fa?ade Repairs/Structural X#Pest Control - Common Areas X&Pest Control - Tenant Premises X Roof Repairs X Door Repair XKeys and Locks X&Access Control - Base Building X( Access Control - Tenant Premises X"Contract Security Services XD lth\PD/*X)Z-q_ !"#$%&'()*+,-./      !! Lab Services!!!!""RODI Maintenance" "X""## Vacuum System# #X##$$Waste PH System$$ $X$%%Compressed Air% %X%%&&Compressed Gasses&& &X&''''''(((((())))))******+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$],d ]dtL=PF0*8X> @//..-- l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)TENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } 0      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018*"TENANT WORK INSURANCE REQUIREMENTS   (a) General Liability! $1,000,000 per occurrence 0 ($1,000,000 personal & advertising injury 0 ($2,000,000 products/completed operations   aggregate$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hwk_SG/iH<0=PF0*8X> @ l  ,  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } } 6      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018*"TENANT WORK INSURANCE REQUIREMENTS   (b) Auto Liability- %$1,000,000 combined single limit (Any 4 ,Auto) for bodily injury and property damage, " hired and non-owned cover. (c) Workers Compensation Statutory Limits Employers Liability!$1,000,000 each accident*!$1,000,000 each employee* $1,000,000 policy limit*5-* or such amounts as are customarily obtained-%by operators of comparable businesses$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4wk_SG/j*==PF0*8X> @ l  A8  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)!SUMMARY OF DIRECTOR COMPENSATIO Subsidiaries of the RegistrantU } y#}       %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018*"TENANT WORK INSURANCE REQUIREMENTS  % (d) Umbrella/Excess Liability! $5,000,000 per occurrence     $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(`Twk_SG/q=PF0*8X> @ l  'G  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2) Subsidiaries of the RegistrantU } 6}  } $ }  } $      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/20180(SUMMARY OF DIRECTOR COMPENSATION PROGRAM         Member  Chairman   Annual  Annual  Fee  Fee Board of Directors~ q  ~   Audit Committee~ 2u~ bCompensation Committee~ "N~ B5-Nominating and Corporate Governance Committee~ .~ bm$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0qeYMAg1`maU-=PF0*8X> @J        l  @T  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??<CONCERT PHARMACEUTICALS INCNoneTABLE OF CONTENTSMARKET INFORMATION!54PURCHASE OF EQUITY SECURITIES64StockBased Compensation!Comparison of the years ended D!Research and development expensComparison of the years (1)Research and development (1) Cash flowsContractual obligationsINDEX TO FINANCIAL STATEMENTSBasis for OpinionBasis for Opini (1)Basis for Opini (2)Basis for Opini (3)3 Fair Value Measurements!NOTES TO CONSOLIDATED FINANCIAL!4 Cash Cash Equivalents and Inv4 Cash Cash Equivalents (1)6 Property and Equipment!7 Accrued Expenses and Other LiNOTES TO CONSOLIDATED (1)NOTES TO CONSOLIDATED (2)NOTES TO CONSOLIDATED (3)NOTES TO CONSOLIDATED (4)!Stockbased compensation expenseNOTES TO CONSOLIDATED (5)NOTES TO CONSOLIDATED (6)NOTES TO CONSOLIDATED (7)NOTES TO CONSOLIDATED (8)!15 Loan Payable and Warrant to !18 Quarterly Financial Informat18 Quarterly Financial (1)!EXECUTIVE OFFICERS AND DIRECTOR!2017 Summary Compensation Table!Narrative to Summary Compensati!111Outstanding Equity Awards at!Payments and benefits provided Director CompensationDirector Compen (1)!Item 12 Security Ownership of C!Item 14 Principal Accountant Fe Part IV Part IV (1)10 Miscellaneous LEASE SUMMARY SHEET234LIST OF EXHIBITS5TABLE OF CONTENTS5TABLE OF CONTE (1)5TABLE OF CONTE (2)5TABLE OF CONTE (3) 24 NOTICES!LANDLORDTENANT RESPONSIBILITY MLANDLORDTENANT (1)!TENANT WORK INSURANCE REQUIREMETENANT WORK INSURANCE (1)TENANT WORK INSURANCE (2)!SUMMARY OF DIRECTOR COMPENSATIOU } 7} $ } I"      %CONCERT PHARMACEUTICALS, INC. 10-K 03/01/2018&Subsidiaries of the Registrant       Name $ Jurisdiction of Organization6 .Concert Pharmaceuticals Securities Corporation   Massachusetts Concert Pharma U.K. Ltd  United Kingdom$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h{ocWK'` =PF0*8X> @ Root Entry FBook  T  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~